Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter P et al. (2025)
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL
Nat Commun, 16 (1), 1041
DOI 10.1038/s41467-025-56318-7, PubMed 39863584

Posadas-Cantera S, Mitsuiki N, Emmerich F, Patiño V, Lorenz HM, Neth O, Dybedal I, Taskén K, Schäffer AA, Grimbacher B, Gámez-Díaz L (2025)
The effect of HLA genotype on disease onset and severity in CTLA-4 insufficiency
Front Immunol, 15, 1447995
DOI 10.3389/fimmu.2024.1447995, PubMed 39835139

Bischof K, Cremaschi A, Eroukhmanoff L, Landskron J, Flage-Larsen LL, Gade A, Bjørge L, Urbanucci A, Taskén K (2024)
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways
Mol Oncol, 19 (1), 81-98
DOI 10.1002/1878-0261.13726, PubMed 39245677